Sinopharm Group Co. Ltd.

SHTDFOTCHealthcare● Active

$2.30

+$0.01(+0.44%)

Market Cap$7.2B

P/E Ratio—

52W High$2.7

52W Low$2.11

Avg Volume122

Open$2.30

Beta0.45

Free Cash Flow Financials Revenue

Sinopharm Group Co. Ltd. (SHTDF) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

SHTDF · free cash flow · updated Jun 9, 2026

Core FCF metrics

SHTDF · FCF · TTM · margin & CAGR

Free cash flow was $12.52B for FY2025 (fiscal year ending 2025-12-31), up 30.7% year-over-year The FCF margin was 2.2%. Five-year CAGR stands at +6.7%.

FY2025 Free Cash Flow$12.52B▲ +30.7% YoY

Trailing 12M (TTM)$19.59Btrailing 4 quarters sum

FCF Margin2.2%$12.52B ÷ revenue

3-Year CAGR-12.3%FY2022 → FY2025

5-Year CAGR+6.7%FY2020 → FY2025

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

SHTDF · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$14.14B(1.62B)$12.52B▲ +30.7%2.2%

FY2024$11.55B(1.97B)$9.58B▼ 35.4%1.6%

FY2023$17.17B(2.34B)$14.84B▼ 20.0%2.5%

FY2022$20.96B(2.42B)$18.55B▲ +163.0%3.4%

FY2021$9.31B(2.26B)$7.05B▼ 22.2%1.4%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

SHTDF · P/FCF · FCF yield · FCF per share

Sinopharm Group Co. Ltd. (SHTDF) trades at a FCF yield of 23.07% and a price-to-free-cash-flow ratio of 0.4x. FCF per share stands at $6.28, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

23.07%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$6.28

TTM FCF ÷ Shares Outstanding

Price / FCF

x0.4

Share Price ÷ FCF per Share

EV / FCF (TTM)

x8.8

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

SHTDF · cash flow statement · operating / investing / financing

For FY2025, Sinopharm Group Co. Ltd. generated $14.14B in operating cash flow and spent 1.62B in capital expenditures, yielding $12.52B in free cash flow.

Operating Activities

+$14.14B

Cash from core business operations

2025-12-31

Investing Activities

−$963.9M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

−$18.69B

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($14.14B) − |CapEx| (1.62B) = FCF ($12.52B)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

SHTDF vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Sinopharm Group Co. Ltd.YOU

SHTDF

$12.52B+30.7%2.2%

64%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Sinopharm Group Co. Ltd. (SHTDF) reported free cash flow of $12.52B for FY2025 (fiscal year ending 2025-12-31), up 30.7% year-over-year. The FCF margin was 2.2%.

Based on available data, Sinopharm Group Co. Ltd. has maintained positive free cash flow for at least 13 fiscal year(s). FCF peaked at $18.55B in FY2022. The 5-year CAGR stands at +6.7%.

Sinopharm Group Co. Ltd.'s FCF yield is 23.07% and price-to-FCF ratio is 0.4x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

SHTDF free cash flow · 8 questions

Sinopharm Group Co. Ltd. free cash flow was $12.52B for FY2025, up 30.7% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $19.59B.

SHTDF free cash flowSHTDF FCFSHTDF FCF 2025SHTDF free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Sinopharm Group Co. Ltd. · Sinopharm Group Co. Ltd. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026